Indivior Pharmaceuticals, Inc.
INDVDrug Manufacturers - Specialty & Generic
$35.37+0.34%As of Oct 30vs prior close
- Market cap
- $4.2B
- P/E (TTM)
- 9.3×
- From 52W high
- −15.44%
- EPS (LTM)
- $3.58
- Revenue (LTM)
- $1.4B
- Net margin
- 32.85%
- Dividend yield
- 0.00%
Nomior Score
66
Steady ProfileSpeculativeTop 15% of the scored universe
Growth52
Quality71
Value54
Momentum68
Resilience56
Growth
+11.20%revenue a year over 3 fiscal years
YE22 $901MLTM $1.4B
Connections
Revenue to profitQ3 FY26
38% of revenue became net profit, up 25 pts on a year.
Latest resultsthird quarter 2026
- Revenue
- $356 million
- Net income
- $137 million
Sales and profit rose in the third quarter, led by record SUBLOCADE revenue and record adjusted EBITDA, driven by strong U.S. dispense unit growth and favorable price, mix and gross-to-net adjustments. Operating expenses declined sharply from the prior year. The company expects to close its merger with Supernus, after which its standalone full-year guidance will no longer apply.
Who owns it
2funds, 1 tracked portfolio